Cannara Biotech

Cannara Biotech Inventory

The Inventory of Cannara Biotech (LOVE.V) as of Oct 29, 2026 is 51.33 M CAD. In the previous year, Inventory was 40.07 M CAD — a change of 28.10% (higher).

Inventory

51.33 MCAD

YoY

28.10%

Last updated:

Inventory of Cannara Biotech is 2025 51.33 M CAD. Inventory of Cannara Biotech was 2024 40.07 M CAD. It decreases by 28.10% higher compared to the previous year.

The Cannara Biotech Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
186,707.00 CAD
Jan 1, 2020
2.24 M CAD
Jan 1, 2021
7.41 M CAD
Jan 1, 2022
18.98 M CAD
Jan 1, 2023
33.77 M CAD
Jan 1, 2024
40.07 M CAD
Jan 1, 2025
51.33 M CAD
The Cannara Biotech Inventory history
YEARInventoryYoY
51.33 MCAD+28.10%
40.07 MCAD+18.66%
33.77 MCAD+77.94%
18.98 MCAD+156.12%
7.41 MCAD+230.57%
2.24 MCAD+1,100.66%
186,707.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cannara Biotech Stock analysis

What does Cannara Biotech do? Cannara Biotech, Inc. generates revenue through its Cannabis operations segment, which includes the cultivation, processing, and sale of dried cannabis and cannabis derivatives for the Canadian market. The company's brand portfolio features Tribal, Nugz, and Orchid CBD, with Orchid CBD specifically targeting the wellness market as a premium CBD-dominant product. The Real estate operations segment involves the management of Farnham and Valleyfield properties, contributing to the company's overall revenue streams. The firm's two mega facilities in Quebec, spanning over 1,650,000 square feet, enable annualized cultivation output of 100,000 kilograms, supporting both product lines and real estate activities. The primary buyers for Cannara's cannabis products are Canadian consumers and businesses within the regulated cannabis market. Tribal and Nugz are positioned as premium cannabis brands, while Orchid CBD serves the wellness segment with its CBD-dominant offerings. Real estate operations focus on leasing and managing the Farnham and Valleyfield buildings, which are part of the company's owned properties. The company's subsidiary structure, including Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc.), supports both operational segments without external partnerships or third-party dependencies. Cannara Biotech's revenue model combines direct sales of cannabis products under its brand portfolio with property management income from its real estate holdings. The company's two facilities in Quebec provide the scale necessary for both cultivation and real estate operations, with the Cannabis operations segment driving most of the product-related sales. The Real estate operations segment complements this by generating steady income from the Farnham and Valleyfield properties, which are integral to the company's asset base. Cannara Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cannara Biotech stock

Inventory of Cannara Biotech is 51.33 M CAD in 2025.

Inventory of Cannara Biotech changed from 40.07 M CAD to 51.33 M CAD, representing a 28.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Cannara Biotech since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Cannara Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cannara Biotech

All Key Metrics — Cannara Biotech